Back to top
more

Exelixis (EXEL)

(Real Time Quote from BATS)

$23.70 USD

23.70
776,773

+0.17 (0.72%)

Updated Apr 26, 2024 02:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for EXEL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Exelixis, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 995 1,308 1,467 1,207 852
Receivables 237 215 283 161 119
Notes Receivable 0 0 0 0 0
Inventories 17 33 27 21 13
Other Current Assets 68 62 58 57 27
Total Current Assets 1,318 1,619 1,835 1,445 1,011
Net Property & Equipment 129 111 104 67 49
Investments & Advances 729 757 371 332 536
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 361 231 112 157 172
Intangibles 64 64 64 64 64
Deposits & Other Assets 0 0 131 72 53
Total Assets 2,942 3,071 2,616 2,137 1,886
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 34 33 24 24 12
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 192 162 226 116 88
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 168 129 87 65 43
Total Current Liabilities 394 324 338 205 143
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 7 9 4 7
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 94 62 8 1 2
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 678 583 406 258 200
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,441 2,537 2,428 2,322 2,242
Retained Earnings -173 -34 -217 -448 -559
Other Equity -4 -15 -1 4 3
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 2,264 2,488 2,211 1,879 1,686
Total Liabilities & Shareholder's Equity 2,942 3,071 2,616 2,137 1,886
Total Common Equity 2,264 2,488 2,211 1,879 1,686
Shares Outstanding 303.10 324.00 316.40 310.20 303.80
Book Value Per Share 7.47 7.68 6.99 6.06 5.55

Fiscal Year End for Exelixis, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 995 1,103 1,267 1,313
Receivables NA 237 248 233 234
Notes Receivable NA 0 0 0 0
Inventories NA 17 25 29 30
Other Current Assets NA 68 67 62 61
Total Current Assets NA 1,318 1,443 1,591 1,638
Net Property & Equipment NA 129 121 115 116
Investments & Advances NA 729 812 839 807
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 361 231 231 230
Intangibles NA 64 64 64 64
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 2,942 2,977 3,142 3,143
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 34 26 26 33
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 192 172 150 139
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 168 179 163 156
Total Current Liabilities NA 394 377 340 328
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 7 6
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 62 74 67
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 678 629 615 588
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,441 2,487 2,531 2,558
Retained Earnings NA -173 -126 11 6
Other Equity NA -4 -14 -14 -9
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 2,264 2,348 2,528 2,555
Total Liabilities & Shareholder's Equity NA 2,942 2,977 3,142 3,143
Total Common Equity 0 2,264 2,348 2,528 2,555
Shares Outstanding 303.10 303.10 310.90 318.30 324.90
Book Value Per Share 0.00 7.47 7.55 7.94 7.86